Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
In her role she will report to CEO Pierluigi Antonelli and will be part of the Executive Leadership Team.
André Kindling has been appointed as the new Angelini Pharma Country Manager Germany. In his role, Kindling will be directly reporting to Luigi Cianci, Chief Commercial Officer – International.
Enza Onnis has been appointed as the new Global Pharma General Counsel at Angelini Pharma.
“La grande incertezza” (The Great Uncertainty) is also a multi-channel communication campaign that uses various communication.
The 1 million euros donation will reinforce research laboratories where COVID-19 was isolated in Italy for the first time.
“Angelini Pharma remains mobilized in the fight against the spread of COVID-19 to protect our doctors, nurses, medical workers on the front lines and all Italians. With Italy. For Italy.” - Pierluigi Antonelli, CEO of Angelini Pharma
Angelini Pharma announces today it has acquired the ThermaCare® global business rights, excluding North America, from GSK. The deal also includes the dedicated US manufacturing site for ThermaCare in Albany, Georgia.
Roberto and Silvestro will report to CEO Pierluigi Antonelli and will be part of the Leadership Team, Angelini Pharma’s executive committee.
Daniela Poggio is joining Angelini Pharma in the new role of Global Communications Head with the aim of strengthening external and internal communications, relationships with the press and social network activities.
With his many years of experience in roles of increasing responsibility in multinationals as well as leading Italian companies , Fabio De Luca is now taking the helm of Global Marketing at Angelini Pharma.
Angelini Pharma announces the acquisition of two Sanofi CHC brands in Germany and Austria for a total of € 47 M.
Sumitomo Dainippon Pharma Co., Ltd. and Angelini S.p.A. announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®.
The new acid-oxidizing solution containing hypoclorous acid and intended for cleansing various kind of wounds, including diabetic foot ulcers, pressure and vascular ulcers, has arrived in Italy.
The depression affects 7.5 million people namely 12.5% of the population in Italy. According to the World Health Organisation (WHO) this illness is the first reason of disability nowadays.